Lynn M. Crosby
Lynn M. Crosby has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Berran Yucesoy
Center for Tobacco Products, Office of Science, U.S. Food and Drug Administration, Silver Spring, Maryland 20993
1 shared publicationCarmine Leggett
Center for Tobacco Products, Office of Science, U.S. Food and Drug Administration, Silver Spring, Maryland 20993
1 shared publication- Călin Adrian Tatu
Faculty of Pharmacy “Victor Babeş” University of Medicine and Pharmacy Timişoara Romania
1 shared publication Guodong Wu
Lovelace Respiratory Research Institute, Albuquerque, New Mexico, 87108
1 shared publicationHammad Irshad
Lovelace Respiratory Research Institute, Albuquerque, New Mexico, 87108
1 shared publicationHans Rosenfeldt
Center for Tobacco Products, Office of Science, U.S. Food and Drug Administration, Silver Spring, Maryland 20993
1 shared publication
Latest Publications
- Open Access
- 10 February 2026
- Published by Bentham Science Publishers Ltd. in The Open Biology Journal
- Vol. 13 (1)
The Strengths and Challenges of New Approach Methods in Genetic Toxicity - Part II
Genetic toxicology originated in 1973 with the Ames test, but it has evolved significantly since then. In the early 2000s, there was great promise for the reduction, refinement, and replacement of animal testing; however, the acceleration of these changes has only occurred over the past 5-7 years. With the advent of new technologies in the laboratory, such as organs-on-a-chip, 3D systems, toxicogenomics, reverse dosimetry/qIVIVE, and PBPK/PBTK/mathematical modeling, along with advances like induced pluripotent stem cell technology, CRISPR-Cas9 gene editing, automation, advanced visual imaging, big data throughput, and machine learning (ML), there is an increasing shift away from animal testing. Part I of the study describes the current genetic toxicity tests required by regulatory agencies for the approval of pharmaceuticals, medical devices, and industrial chemicals, as well as their limitations. This part explores how new approach methods (NAMs),already in use or in qualification/validation, can help bridge those gaps, acknowledging that such assays must meet rigorous standards for fitness for purpose, domain of applicability, and context of use. Additionally, the status of regulatory acceptance and implementation is discussed.
- 10 February 2026
- Published by Bentham Science Publishers Ltd. in The Open Biology Journal
- Vol. 13 (1)
Open AccessThe Strengths and Challenges of New Approach Methods in Genetic Toxicity - Part II
Genetic toxicology originated in 1973 with the Ames test, but it has evolved significantly since then. In the early 2000s, there was great promise for the reduction, refinement, and replacement of animal testing; however, the acceleration of these changes has only occurred over the past 5-7 years. With the advent of new technologies in the laboratory, such as organs-on-a-chip, 3D systems, toxicogenomics, reverse dosimetry/qIVIVE, and PBPK/PBTK/mathematical modeling, along with advances like induced pluripotent stem cell technology, CRISPR-Cas9 gene editing, automation, advanced visual imaging, big data throughput, and machine learning (ML), there is an increasing shift away from animal testing. Part I of the study describes the current genetic toxicity tests required by regulatory agencies for the approval of pharmaceuticals, medical devices, and industrial chemicals, as well as their limitations. This part explores how new approach methods (NAMs),already in use or in qualification/validation, can help bridge those gaps, acknowledging that such assays must meet rigorous standards for fitness for purpose, domain of applicability, and context of use. Additionally, the status of regulatory acceptance and implementation is discussed.
- Open Access
- 21 November 2025
- Published by Bentham Science Publishers Ltd. in The Open Biology Journal
- Vol. 12 (1)
The Strengths and Challenges of Conventional Short-Term Genetic Toxicity Assays
The field of toxicology is moving forward rapidly, and the trend is toward non-animal testing. In terms of genetic toxicity testing, there are many accepted OECD test guidelines reliant on in vivo animal models. In the interest of providing a complete picture of the methods available for both animal-derived and non-animal genetic toxicity testing, Part I in the series discusses the existing short-term accepted test methodologies, while Part II examines available New Approach Methodologies (NAMs). The advantages and disadvantages of the current methodologies are discussed here, while those of new methodologies and the current regulatory landscape relative to them are reserved for discussion in Part II.
- 21 November 2025
- Published by Bentham Science Publishers Ltd. in The Open Biology Journal
- Vol. 12 (1)
Open AccessThe Strengths and Challenges of Conventional Short-Term Genetic Toxicity Assays
The field of toxicology is moving forward rapidly, and the trend is toward non-animal testing. In terms of genetic toxicity testing, there are many accepted OECD test guidelines reliant on in vivo animal models. In the interest of providing a complete picture of the methods available for both animal-derived and non-animal genetic toxicity testing, Part I in the series discusses the existing short-term accepted test methodologies, while Part II examines available New Approach Methodologies (NAMs). The advantages and disadvantages of the current methodologies are discussed here, while those of new methodologies and the current regulatory landscape relative to them are reserved for discussion in Part II.
- 14 March 2024
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 27 (3) , 378-386
Unravelling the Risk of Poisoning From Nicotine-Containing Tobacco Products in Children Less Than Five Years of Age
For decades, young children in the United States have been accidentally poisoned by traditional tobacco products and the yearly incidence has slowly increased. More poisonings have accompanied the introduction of new products such as e-cigarettes and dissolvable tobacco, with renewed public attention. Using toxicological principles of human health risk assessment, published data from prior exposures, and information about the content and characteristics of specific products, I estimated the acute toxicological risk from exposure to various types and quantities of tobacco products for children <5 years old. Approximate reference levels for a non-lethal oral dose of nicotine were derived: A higher level potentially requiring medical care (0.2 mg per kg) and a lower level not potentially requiring medical care (0.04 mg per kg). A weight-based oral lowest lethal dose (LDLO) of 1–14 mg per kg in children <5 years old is estimated from the cited LDLOs in adults. I provide tables relating e-liquid concentration and volume to the oral LDLO in children <5 years old by weight and describing the amount of other tobacco products expected to result in lethality. Communications about safe storage practices should focus on the benefits of keeping any nicotine-containing product out of the reach of young children, and adults can be reminded to always reengage child-resistant closures on packages and call a poison center for accidental exposures. Healthcare providers, families, or any member of the public can also make reports about unexpected health or safety concerns related to tobacco products to the FDA using its online Safety Reporting Portal at https://www.fda.gov/TobaccoProducts/PublicHealthScienceResearch/ucm377563.htm. Tobacco products, particularly electronic nicotine delivery system (ENDS) liquids are highly toxic to children <5 years old in small amounts. Given that the concentration of nicotine in ENDS is 3 to 72 mg per mL, the lethal dose (LDLO) is expected to be 13–40 mL in a bottle containing a solution of 3 mg per mL liquid nicotine but may be as low as ½–2 mL in a bottle containing a highly concentrated solution of 72 mg per mL liquid nicotine. Features such as flow restrictors, child-resistant closures, and communication of safe storage practices to parents can help to lessen the morbidity and mortality from poisoning.
- 14 March 2024
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 27 (3) , 378-386
Unravelling the Risk of Poisoning From Nicotine-Containing Tobacco Products in Children Less Than Five Years of Age
For decades, young children in the United States have been accidentally poisoned by traditional tobacco products and the yearly incidence has slowly increased. More poisonings have accompanied the introduction of new products such as e-cigarettes and dissolvable tobacco, with renewed public attention. Using toxicological principles of human health risk assessment, published data from prior exposures, and information about the content and characteristics of specific products, I estimated the acute toxicological risk from exposure to various types and quantities of tobacco products for children <5 years old. Approximate reference levels for a non-lethal oral dose of nicotine were derived: A higher level potentially requiring medical care (0.2 mg per kg) and a lower level not potentially requiring medical care (0.04 mg per kg). A weight-based oral lowest lethal dose (LDLO) of 1–14 mg per kg in children <5 years old is estimated from the cited LDLOs in adults. I provide tables relating e-liquid concentration and volume to the oral LDLO in children <5 years old by weight and describing the amount of other tobacco products expected to result in lethality. Communications about safe storage practices should focus on the benefits of keeping any nicotine-containing product out of the reach of young children, and adults can be reminded to always reengage child-resistant closures on packages and call a poison center for accidental exposures. Healthcare providers, families, or any member of the public can also make reports about unexpected health or safety concerns related to tobacco products to the FDA using its online Safety Reporting Portal at https://www.fda.gov/TobaccoProducts/PublicHealthScienceResearch/ucm377563.htm. Tobacco products, particularly electronic nicotine delivery system (ENDS) liquids are highly toxic to children <5 years old in small amounts. Given that the concentration of nicotine in ENDS is 3 to 72 mg per mL, the lethal dose (LDLO) is expected to be 13–40 mL in a bottle containing a solution of 3 mg per mL liquid nicotine but may be as low as ½–2 mL in a bottle containing a highly concentrated solution of 72 mg per mL liquid nicotine. Features such as flow restrictors, child-resistant closures, and communication of safe storage practices to parents can help to lessen the morbidity and mortality from poisoning.
- 6 October 2020
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 180 (1) , 122-135
Smoke Chemistry, In Vitro Cytotoxicity, and Genotoxicity Demonstrates Enhanced Toxicity of Cigarillos Compared With Cigarettes
There has been limited toxicity testing of cigarillos, including comparison to cigarettes. This study compared the smoke chemistry and the cytotoxic and genotoxic potential of 10 conventional cigarettes and 10 cigarillos based on the greatest market share. Whole smoke and total particulate matter (TPM) were generated using the Canadian Intense and International Organization for Standardization puffing protocols. Tobacco-specific nitrosamines, carbonyls, and polycyclic aromatic hydrocarbons were measured using gas chromatography-mass spectrometry. TPM smoke extracts were used for the in vitro assays. Cytotoxicity was assessed in human bronchial epithelial continuously cultured cell line cells using the neutral red uptake assay. Genotoxic potential was assessed using the micronucleus (human lung adenocarcinoma continuously cultured cell line cells), Ames, and thymidine kinase assays. TPM from all cigarillos tested was more cytotoxic than cigarettes. Micronucleus formation was significantly greater for cigarillos compared with cigarettes at the highest dose of TPM, with or without rat liver S9 fraction. In the Ames test +S9, both tobacco products exhibited significant dose-dependent increases in mutation frequency, indicating metabolic activation is required for genotoxicity. In the thymidine kinase assay +S9, cigarillos showed a significantly enhanced mutation frequency although both tobacco products were positive. The levels of all measured polycyclic aromatic hydrocarbons, tobacco-specific nitrosamines, and carbonyls (except acrolein) were significantly greater in cigarillos than cigarettes. The Canadian Intense puffing protocol demonstrated increased smoke constituent levels compared with International Organization for Standardization. Even though the gas vapor phase was not tested, the results of this study showed that under the tested conditions the investigated cigarillos showed greater toxicity than comparator cigarettes. This study found that there is significantly greater toxicity in the tested U.S. marketed cigarillos than cigarettes for tobacco constituent levels, cytotoxicity, and genotoxicity. These findings are important for understanding the human health toxicity from the use of cigarillos relative to cigarettes and for building upon knowledge regarding harm from cigarillos to inform risk mitigation strategies.
- 6 October 2020
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 180 (1) , 122-135
Smoke Chemistry, In Vitro Cytotoxicity, and Genotoxicity Demonstrates Enhanced Toxicity of Cigarillos Compared With Cigarettes
There has been limited toxicity testing of cigarillos, including comparison to cigarettes. This study compared the smoke chemistry and the cytotoxic and genotoxic potential of 10 conventional cigarettes and 10 cigarillos based on the greatest market share. Whole smoke and total particulate matter (TPM) were generated using the Canadian Intense and International Organization for Standardization puffing protocols. Tobacco-specific nitrosamines, carbonyls, and polycyclic aromatic hydrocarbons were measured using gas chromatography-mass spectrometry. TPM smoke extracts were used for the in vitro assays. Cytotoxicity was assessed in human bronchial epithelial continuously cultured cell line cells using the neutral red uptake assay. Genotoxic potential was assessed using the micronucleus (human lung adenocarcinoma continuously cultured cell line cells), Ames, and thymidine kinase assays. TPM from all cigarillos tested was more cytotoxic than cigarettes. Micronucleus formation was significantly greater for cigarillos compared with cigarettes at the highest dose of TPM, with or without rat liver S9 fraction. In the Ames test +S9, both tobacco products exhibited significant dose-dependent increases in mutation frequency, indicating metabolic activation is required for genotoxicity. In the thymidine kinase assay +S9, cigarillos showed a significantly enhanced mutation frequency although both tobacco products were positive. The levels of all measured polycyclic aromatic hydrocarbons, tobacco-specific nitrosamines, and carbonyls (except acrolein) were significantly greater in cigarillos than cigarettes. The Canadian Intense puffing protocol demonstrated increased smoke constituent levels compared with International Organization for Standardization. Even though the gas vapor phase was not tested, the results of this study showed that under the tested conditions the investigated cigarillos showed greater toxicity than comparator cigarettes. This study found that there is significantly greater toxicity in the tested U.S. marketed cigarillos than cigarettes for tobacco constituent levels, cytotoxicity, and genotoxicity. These findings are important for understanding the human health toxicity from the use of cigarillos relative to cigarettes and for building upon knowledge regarding harm from cigarillos to inform risk mitigation strategies.
- 6 April 2018
- Published by Oxford University Press (OUP) in Environmental Toxicology and Chemistry
- Vol. 37 (8) , 2098-2111
Toxicological and chemical studies of wastewater from hydraulic fracture and conventional shale gas wells
New technology has enabled recovery of inaccessible natural gas shale deposits, however, the potential impacts to human health from the migration of brines into drinking water or surface spills are unknown. To provide information that can inform these potential impacts, chemical characterization and in vitro toxicologic testing were conducted using pre‐ and post‐injection waters from conventional and unconventional oil and gas wells. Wastewater concentrations may be diluted or reduced by fate and transport processes when released into the environment by unknown amounts, and lab studies only imply potential effects. In acute cytotoxicity and wound healing assays, there was dose‐dependent toxicity in human and rat cells with growth promotion at low concentrations. Lethality was measured in time studies up to 10 days post‐injection. Produced water samples from both well types were equally toxic to human cells and were corrosive at high concentrations. Measurement of protein and gene expression identified metabolic pathways responding to both well types as NQO1 oxidative stress‐responsive enzyme and tight junction protein genes. A KCl sample of matched ionic strength showed a different toxicity profile than produced waters, indicating that salts alone were not the cause of toxicity. Organic chemicals and branched alkanes were present in hydraulic fracture wells and mainly branched alkanes were present in conventional wells. One organic substance was still present after 240 days. The known properties of these chemicals include potential toxicity to multiple human organs, sensitization, irritation, developmental effects and tumor promotion, depending upon the concentrations and synergystic effects of chemicals during exposure. This article is protected by copyright. All rights reserved
- 6 April 2018
- Published by Oxford University Press (OUP) in Environmental Toxicology and Chemistry
- Vol. 37 (8) , 2098-2111
Toxicological and chemical studies of wastewater from hydraulic fracture and conventional shale gas wells
New technology has enabled recovery of inaccessible natural gas shale deposits, however, the potential impacts to human health from the migration of brines into drinking water or surface spills are unknown. To provide information that can inform these potential impacts, chemical characterization and in vitro toxicologic testing were conducted using pre‐ and post‐injection waters from conventional and unconventional oil and gas wells. Wastewater concentrations may be diluted or reduced by fate and transport processes when released into the environment by unknown amounts, and lab studies only imply potential effects. In acute cytotoxicity and wound healing assays, there was dose‐dependent toxicity in human and rat cells with growth promotion at low concentrations. Lethality was measured in time studies up to 10 days post‐injection. Produced water samples from both well types were equally toxic to human cells and were corrosive at high concentrations. Measurement of protein and gene expression identified metabolic pathways responding to both well types as NQO1 oxidative stress‐responsive enzyme and tight junction protein genes. A KCl sample of matched ionic strength showed a different toxicity profile than produced waters, indicating that salts alone were not the cause of toxicity. Organic chemicals and branched alkanes were present in hydraulic fracture wells and mainly branched alkanes were present in conventional wells. One organic substance was still present after 240 days. The known properties of these chemicals include potential toxicity to multiple human organs, sensitization, irritation, developmental effects and tumor promotion, depending upon the concentrations and synergystic effects of chemicals during exposure. This article is protected by copyright. All rights reserved